Avita Medical press release link here.
AmpliPhi BioSciences Corporation (OTC: APHB) (“AmpliPhi”), the leader in the discovery and development of bacteriophage-based therapies to treat drug resistant bacterial infections, announced today a Collaborative Research and Development Agreement (CRADA) with the United States Army Medical Research and Materiel Command (USAMRMC) and the Walter Reed Army Institute of Research (WRAIR).
Leading healthcare fund manager, BioScience Managers, has moved into the rapidly growing anti-infectives market with a US$1m investment into Bulletin Board-listed AmpliPhi Biosciences Corporation (APHB.PK).
Read more about BioScience Managers Banks on Growth in Anti-Infectives Market
International life sciences investment group and major shareholder of Bioxyne, today backed the Bioxyne Board in their decision to withdraw from the company’s proposed transaction with Vitality Devices (See the announcement here).
Read more about Bioscience Managers Supports Bioxyne Decision on Transaction
A LEADING Australasian healthcare fund has generated a unit price of $1.81 for every dollar invested four and a half years ago, prompting its managers to urge superannuation funds to ‘strongly’ consider backing proven managers in the healthcare sector to secure better returns for their members.
(Melbourne) Leading Asia Pacific healthcare fund manager, BioScience Managers Pty Ltd, today announced a $3m investment in innovative New Zealand asthma technology company Nexus6.
BioScience Managers Pty Ltd (formerly Octa Phillip Bioscience Managers) today fully endorsed the move by Bioxyne Ltd (ASX:BXN) to acquire Asia Pacific medical device company, Vitality Devices Pty Ltd.
Read more about BioScience Managers Backs Bioxyne Move
Leading Australasian bioscience fund manager, Octa Phillip Bioscience Managers (Bioscience Managers), today announced a successful first close on its second fund, the Asia Pacific Healthcare Fund II, which has so far attracted $55 million from Australian Institutions, IOOF and MIESF.
Read more about Bioscience Managers Announces First Close on New Healthcare Fund
IB Australian Bioscience Fund I, managed by Octa Phillip Bioscience Managers (OPBM, formerly IB Managers) has today entered into a conditional Subscription Agreement to invest NZD$2.5 million into Claridge Capital...
Read more about Australian Bioscience Fund I to invest in Sea Dragon Marine Oils
Octa Phillip Bioscience Managers provision of management services and support to Union MedTech Plc, the UK listed medical technology investment vehicle, today received a boost with Union Medtech’s announcement of...